127 related articles for article (PubMed ID: 15380342)
1. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.
Deeg HJ; Jiang PY; Holmberg LA; Scott B; Petersdorf EW; Appelbaum FR
Leuk Res; 2004 Nov; 28(11):1177-80. PubMed ID: 15380342
[TBL] [Abstract][Full Text] [Related]
2. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.
Deeg HJ; Gotlib J; Beckham C; Dugan K; Holmberg L; Schubert M; Appelbaum F; Greenberg P
Leukemia; 2002 Feb; 16(2):162-4. PubMed ID: 11840280
[TBL] [Abstract][Full Text] [Related]
3. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.
Scott BL; Ramakrishnan A; Fosdal M; Storer B; Becker P; Petersdorf S; Deeg HJ
Br J Haematol; 2010 Jun; 149(5):706-10. PubMed ID: 20331464
[TBL] [Abstract][Full Text] [Related]
4. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
5. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
6. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome.
Maciejewski JP; Risitano AM; Sloand EM; Wisch L; Geller N; Barrett JA; Young NS
Br J Haematol; 2002 Apr; 117(1):119-26. PubMed ID: 11918541
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
9. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
11. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
12. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
13. Antithymocyte globulin for patients with myelodysplastic syndrome.
Molldrem JJ; Caples M; Mavroudis D; Plante M; Young NS; Barrett AJ
Br J Haematol; 1997 Dec; 99(3):699-705. PubMed ID: 9401087
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
15. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
[TBL] [Abstract][Full Text] [Related]
16. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
Tsimberidou AM; Giles FJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):277-86. PubMed ID: 12113051
[TBL] [Abstract][Full Text] [Related]
18. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
20. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
